Related references
Note: Only part of the references are listed.Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Cancer therapy in the necroptosis era
Z. Su et al.
CELL DEATH AND DIFFERENTIATION (2016)
Bioactivities, isolation and purification methods of polysaccharides from natural products: A review
Lei Shi
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2016)
Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance
David J. Pinato et al.
CANCER TREATMENT REVIEWS (2013)
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis
Angelina V. Vaseva et al.
CELL (2012)
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Gregory J. Riely et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Escin, a Pentacyclic Triterpene, Chemosensitizes Human Tumor Cells through Inhibition of Nuclear Factor-κB Signaling Pathway
Kuzhuvelil B. Harikumar et al.
MOLECULAR PHARMACOLOGY (2010)
The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage
Ho-Chou Tu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer
Xianqing Jin et al.
CANCER SCIENCE (2008)
Constitutive and inducible nuclear factor-κB in immortalized normal human bronchial epithelial and non-small cell lung cancer cell lines
Johnson Baby et al.
CANCER LETTERS (2007)
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro
Chun-Chi Liang et al.
NATURE PROTOCOLS (2007)
Expression of nuclear factor-κB and its clinical significance in nonsmall-cell lung cancer
Zhenfa Zhang et al.
ANNALS OF THORACIC SURGERY (2006)
NF-κB and IKK as therapeutic targets in cancer
HJ Kim et al.
CELL DEATH AND DIFFERENTIATION (2006)
New dammarane-type saponins from the galls of Sapindus mukorossi
YH Kuo et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2005)
On the origins of triterpenoid skeletal diversity
R Xu et al.
PHYTOCHEMISTRY (2004)
The IKKNF-kappa B system: A treasure trove for drug development
M Karin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
NF-κB in cancer:: From innocent bystander to major culprit
M Karin et al.
NATURE REVIEWS CANCER (2002)
Inhibition of nuclear factor κB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation
DR Jones et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2002)
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
E Steels et al.
EUROPEAN RESPIRATORY JOURNAL (2001)
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
AS Baldwin
JOURNAL OF CLINICAL INVESTIGATION (2001)
Molecular and genetic aspects of lung cancer
WN Rom et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Share Paper
